Prevention of Postoperative Delirium With Donepezil

Technical University of Munich

Status and phase: Completed; Phase 4

Conditions: Cognitively Normal Elderly Individuals

Treatments: Drug: Donepezil

Study type: Interventional

Funder types: Other

Identifiers

NCT00220896

PSYTUM1

Details and patient eligibility

About

Patients undergoing hip or knee joint replacement at the age of 70 years or above who are cognitively unimpaired will receive donepezil or matching placebo before (over 5-7 days), during and after (over 7 days) surgery. The incidence of delirium will be monitored at 3 days, 7 days, and 49 days following surgery. We hypothesize that the incidence of delirium can be lowered from 20 per cent to 10 per cent by the intervention.

Enrollment: 37 patients

Sex: All

Ages: 70+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Cognitively healthy, elective hip or knee replacement

Exclusion criteria

• Ongoing cholinergic treatment, dementia, delirium, acute physical illness

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind